Head-to-head evidence
Azvudine vs CL-197
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Azvudine · FNC
Marketed by Henan Genuine Biotech
NCT04303598 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial testing whether azvudine achieves viral suppression as well as an established comparator, using a recognized clinical measure of HIV control, but results are not yet posted so the outcome is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
CL-197
Developed by Henan Genuine Biotech
NCT05944848 · Phase 1 · completed
The study randomly assigned healthy volunteers to active drug or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. However, it tested only safety and drug levels in healthy volunteers rather than any HIV outcome, and results have not been posted.
Next expected readout: December 2026 · NCT07308782 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Azvudine's landscape · CL-197's landscape